Comprising more than 60% of all therapeutic targets, G-protein coupled receptor and kinase targets are arguably the most exciting proteins in pharmacology today. Yet, despite massive investment spanning decades, translating early research to clinical success remains frustratingly slow. New approaches are needed that acknowledge and integrate structural, functional and systems components, to accelerate time-to-market.
By attending Visiongain`s GPCR and Kinase Targets conference, you will engage with leading decision makers and thought leaders, enabling you to:
- Improve the efficacy of assays to enhance 7 transmembrane and kinase drug discovery
- Incorporate improved computational models to evaluate drug-receptor interactions and allosteric modulation of downstream signalling pathways
- Evaluate gene splicing for μ-opiod drug development
- Target chemogenomic, Wnt and aneuploid-specific pathways for cancer therapy
- Employ more accurate siRNA screens to map signalling networks
- Dissect variability in chemotherapy through systems pharmacology
- Utilise developments in HTS technology to improve patient stratification
- Employ alternatives to mass spectrometry when undertaking research
- Integrate cell-signalling and systems biology insights into treatments for complex diseases
- Selectively activate and quantify beta-arrestin biased ligands for analgesia and heart disease
- Better modulate parathyroid hormone release to treat osteoporosis
- Assess pharmacotherapies in clinical development for pulmonary, neurodevelopmental and antipsychotic diseases
